1. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes technology and therapeutics. 2011 Jun;13(Suppl 1):S103–8. [PubMed] 2. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011 Mar 12;377(9769):924–31. [PubMed]
3. Ib Jonassen SH, Ribel Ulla, Hoeg-Jensen Thomas, et al. Insulin degludec is a new generation ultra-long acting bsal insulin with a unique mechansim of protraction based on multi-hexamer formation. 2010.
4. Erica Nishimura ASOr, Hansen Bo Flack, Stidsen Carsten, et al. Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potentital. 2010.
5. Luigi F, Meneghini SLA, Bain Stephen, et al. 2011. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes.
6. Peter Kurtzhals TH, Strauss Holger M, B[Oslash]ttcher Susanne G, Granhall Charlotte, Haahr Hanne, Jonassen Ib. Multi-Hexamer Formation is the Underlying Mechanism behind the Ultra-Long Glucose-Lowering Effect of Insulin Degludec. 2011.
7. Owens DR. Insulin preparations with prolonged effect. Diabetes Technology and Therapeutics. 2011 Jun;13(Suppl 1):S5–14. [PubMed] 8. Danne T, Bolinder J. New insulins and insulin therapy. International Journal of Clinical Practice Supplement. 2011 Feb;(170):26–30. [PubMed] 9. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011 Mar;34(3):661–5. [PMC free article] [PubMed]
10. Luigi F, Meneghini PDH, Wendisch Ulrich, Ratner Robert E, Endhal Lars A, Johansen Thue, Lyby Karsten, Jendle Johan H, Roberts Anthony P, Devries J Hans, Birkeland K[Aring]re I. 2010. Insulin Degludec, a New Generation Ultra-Long Acting Insulin, in a Mealtime + Basal Regimen in People with Type 1 Diabetes: Comparison to insulin Glargine.
11. Simon Heller AMOF, Pei Huiling, Russell-Jones David. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basalbolus trial in type 1 diabetes. 2011.
12. Bernard Zinman GF, Rao Paturi V, Thomas Nihal, et al. 2010. Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3 times weekly in people with type 2 diabetes: comparison to insulin glargine.
13. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011 Mar;34(3):669–74. [PMC free article] [PubMed]
14. Tim Heise CT, Cuddihy Bob Micheal, Davidson Jaime, et al. 2010. Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive subjects with type 2 diabetes: comparison with insulin.
15. Allan Vaag LAL, Franek Edward, Weng Jianping, et al. Use of a new basal insulin with a bolus boost (idegasp) in type 2 diabetes: comparison with biphasic insulin aspart 30 (BIAap 30) 2011.
16. Alan J, Garber ABK, Anne Marrie O, Francisco, Endahl Lars, Priscilla A. Hollander insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes. 2011.
17. Irl B, Hirsch EF, Courreges Jean-Pierre, Mersebach Henriette, Dykiel Patrik, Bruce W. 2011. Bode efficacy and safety of a new basal insulin with a bolus boost (IDegasp) used once daily in combination with insulin aspart (IAsp) in people with type 1 diabetes.
18. Tim Heise LH, Nosek Leszek, Feldmann Andre, Rasmussen S[Oslah]ren, Haahr Hanne. The pharmacodynamic variability of insulin degludec isconsistently lower than insulin glargine over 24 hours at steady state. 2011.
19. Danne T, Bolinder J. New insulins and insulin therapy. International Journal of Clinical Practice. 2011 Feb;65(Suppl 170):26–30. [PubMed] 20. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clinical Therapeutics. 2008 Nov;30(11):1976–87. [PubMed]
21. al. Ne. IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 2011.
22. Hirsch IB. Insulin analogues. The New England Journal of Medicine. 2005 Jan 13;352(2):174–83. [PubMed] 23. Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technology and Therapeutics. 2011 Jun;13(Suppl 1):S33–42. [PubMed]
24. Yn Bi XL, Yang Daizhi, Hao Yuantao, Liang Hua, Zhu Dalong, Weng Jianping. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses. Journal of Diabetes Investigation. 2011
25. Reynolds LR. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary. Postgraduate Medicine. 2010 Jan;122(1):201–3. [PubMed] 26. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012 Jan;55(1):51–62. [PMC free article] [PubMed] 27. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: A cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012 Mar;55(3):644–53. [PMC free article] [PubMed]